1. Home
  2. LTBR vs TECX Comparison

LTBR vs TECX Comparison

Compare LTBR & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$11.20

Market Cap

575.6M

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$30.51

Market Cap

545.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTBR
TECX
Founded
1992
2019
Country
United States
United States
Employees
N/A
60
Industry
Professional Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
575.6M
545.3M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
LTBR
TECX
Price
$11.20
$30.51
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$75.25
AVG Volume (30 Days)
707.1K
167.5K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.85
$14.39
52 Week High
$31.34
$35.99

Technical Indicators

Market Signals
Indicator
LTBR
TECX
Relative Strength Index (RSI) 48.67 53.52
Support Level $9.78 $17.71
Resistance Level $11.53 $32.27
Average True Range (ATR) 0.73 1.57
MACD 0.16 -0.27
Stochastic Oscillator 76.92 53.81

Price Performance

Historical Comparison
LTBR
TECX

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: